Women carrying BRCA1/2 mutations diagnosed with breast cancer should be informed by a multidisciplinary team about their cancer prognosis, estimated hereditary risk of second tumors, treatment and risk reduction options, and sequelae, and side effects of these measures. In this way, women can make a guided decision with qualified information and thus receive personalized treatment.